+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mycobacterium Tuberculosis Market - Global Forecast 2026-2032- Product Image
Mycobacterium Tuberculosis Market - Global Forecast 2026-2032- Product Image
Sale

Mycobacterium Tuberculosis Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6126690
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Mycobacterium Tuberculosis Market is projected to reach USD 4.33 Billion in 2026. It is expected to continue growing at a CAGR of 6.91%, reaching USD 6.52 Billion by 2032.

Mycobacterium Tuberculosis: Executive Summary and Strategic Context

Mycobacterium tuberculosis is the bacterium responsible for most tuberculosis (TB) infections, a communicable disease that primarily affects the lungs but can involve other organs. Its continuing importance reflects persistent transmission, latent infection, drug resistance, diagnostic complexity, and the need for coordinated public-health and clinical responses. Effective control depends on timely detection, appropriate treatment, contact investigation, prevention of progression from latent infection, and strong infection-prevention practices.

How Diagnostics, Drug Resistance, and Prevention Are Reshaping TB Control

TB control is being transformed by faster molecular diagnostics, improved testing for drug resistance, digital adherence tools, and more targeted approaches to screening high-risk populations. These advances are shifting practice away from reliance on prolonged empirical treatment and toward microbiologically informed care. At the same time, multidrug-resistant and rifampicin-resistant TB require specialized regimens, stronger laboratory networks, treatment monitoring, and stewardship to preserve the effectiveness of available medicines. Prevention increasingly combines vaccination, latent-TB testing and treatment, ventilation, contact tracing, and action on social determinants such as overcrowding and limited healthcare access.

Artificial Intelligence Is Strengthening Detection, Triage, and Program Management

Artificial intelligence can support TB programs by identifying radiographic patterns, prioritizing people for confirmatory testing, improving case-finding in settings with limited specialist capacity, and helping laboratories interpret complex data. It can also assist treatment adherence monitoring, risk stratification, supply planning, and surveillance analytics. These applications require representative training data, external validation, transparent performance measures, clinical oversight, privacy safeguards, and pathways for confirmatory testing. AI should augment-not replace-microbiological diagnosis, professional judgment, patient consent, and equitable access to care.

Regional Priorities Differ Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America generally emphasizes targeted screening, molecular confirmation, contact investigations, and management of latent infection, while Latin America must combine urban case-finding with stronger laboratory and treatment access across diverse health systems. Europe faces continued challenges from migration-linked vulnerability, aging populations, and drug-resistant disease, requiring cross-border continuity of care. The Middle East needs resilient services for displaced and mobile populations, reliable diagnostics, and uninterrupted treatment during humanitarian disruption. Africa’s priorities include integrating TB and HIV services, expanding laboratory capacity, and addressing access barriers. Asia-Pacific contains highly diverse epidemiological and health-system conditions, making decentralized diagnosis, community-based care, drug-resistance surveillance, and targeted prevention particularly important.

ASEAN, BRICS, the European Union, G7, GCC, and NATO Need Coordinated TB Action

ASEAN cooperation can support cross-border referral, migrant-friendly services, laboratory strengthening, and shared surveillance approaches. BRICS members can advance collaboration on drug-resistant TB research, diagnostics, manufacturing capacity, and implementation science. The European Union benefits from harmonized surveillance, screening guidance, and continuity of care across borders. G7 countries can contribute research, financing, technical assistance, and support for resilient health systems. GCC members should prioritize screening and treatment continuity for mobile workforces while strengthening infection prevention. NATO’s relevance is centered on health-security preparedness, interoperability, and continuity of essential medical services during crises; these activities should complement civilian public-health leadership.

Country-Level Priorities Span Innovation, Access, Resistance, and Continuity of Care

Australia should sustain targeted screening, surveillance, and culturally appropriate services for remote and at-risk communities. Brazil and Mexico need integrated community case-finding, laboratory access, and continuity of care across urban and underserved areas. Canada, the United Kingdom, France, Germany, Italy, and Spain should maintain vigilant surveillance, migrant-inclusive services, and strong management of latent and drug-resistant TB. China and India require continued expansion of rapid diagnostics, treatment quality, and prevention among high-risk populations. Japan and South Korea should address aging-related vulnerability, healthcare-associated transmission, and drug-resistance monitoring. Russia requires sustained attention to drug-resistant disease, laboratory quality, and treatment adherence. In the United States, targeted testing, contact investigation, latent-TB treatment, and rapid molecular diagnosis remain central to prevention and control.

Industry Leaders Should Prioritize Interoperable Diagnostics, Patient-Centered Care, and Responsible AI

Leaders should strengthen end-to-end diagnostic pathways, including specimen transport, rapid molecular testing, drug-susceptibility assessment, and referral for complex disease. Product and service design should support shorter, safer, patient-centered regimens where clinically appropriate, while minimizing adherence barriers and treatment interruption. Organizations should build interoperable data systems that connect laboratories, clinics, public-health authorities, and community providers without compromising privacy. AI investments should be tied to validated clinical use cases, independent monitoring, and equitable performance. Partnerships with national programs, local communities, laboratories, and humanitarian organizations are essential for implementation, procurement resilience, and sustained access.

Methodology Combines Epidemiological Evidence, Program Context, and Structured Geographic Comparison

This executive summary uses the subject definition-Mycobacterium tuberculosis-and synthesizes established public-health, clinical, laboratory, and health-system considerations relevant to TB control. The analysis is organized across six specified regions, six international groupings, and fifteen countries to identify recurring priorities and contextual differences. It emphasizes verified principles from infectious-disease practice, including transmission reduction, microbiological confirmation, drug-resistance management, prevention of progression, and continuity of care. No market estimates, market sizing, market shares, forecasts, or company-specific claims are used.

Sustained TB Progress Depends on Combining Science, Systems, and Equity

The TB landscape is shaped by the interaction of pathogen biology, drug resistance, diagnostic access, social vulnerability, and health-system resilience. Faster testing and responsible AI can improve decisions, but their value depends on dependable laboratories, trained personnel, affordable treatment, patient support, and trusted public-health institutions. The strongest strategies will integrate prevention, early diagnosis, effective treatment, surveillance, and cross-border coordination while adapting delivery to regional and country conditions. Equity and continuity should remain the central measures of progress.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Mycobacterium Tuberculosis Market, by Drug Class
7.1. Introduction
7.2. First Line Drugs
7.3. Second Line Drugs
8. Mycobacterium Tuberculosis Market, by Test Type
8.1. Introduction
8.2. Culture Tests
8.3. Interferon Gamma Release Assays
8.4. Microscopy Tests
8.5. Molecular Tests
8.5.1. Lamp
8.5.2. Pcr
8.5.3. Xpert Mtb Rif
8.6. Skin Tests
9. Mycobacterium Tuberculosis Market, by Treatment Regimen
9.1. Introduction
9.2. Drug Resistant Treatment
9.2.1. Extensively Drug Resistant
9.2.2. Multidrug Resistant
9.3. Drug Susceptible Treatment
10. Mycobacterium Tuberculosis Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Laboratories
10.5. Research Institutes
11. Mycobacterium Tuberculosis Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Mycobacterium Tuberculosis Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Mycobacterium Tuberculosis Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Mycobacterium Tuberculosis Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Molecular Inc.
16.2. Actiza Pharmaceutical Private Limited
16.3. Anuh Pharma Ltd.
16.4. AstraZeneca PLC
16.5. Bayer AG
16.6. Becton, Dickinson and Company
16.7. bioMérieux SA
16.8. Cadila Healthcare Ltd.
16.9. CapitalBio
16.10. Care Formulation Labs Private Limited
16.11. Cepheid, Inc.
16.12. Cipla Ltd.
16.13. DaAN Gene Company
16.14. Eiken Chemical Co., Ltd.
16.15. GlaxoSmithKline plc
16.16. Hain Lifescience GmbH
16.17. Hetero Labs Ltd.
16.18. Hologic, Inc.
16.19. Johnson & Johnson
16.20. Lupin Limited
16.21. Macleods Pharmaceuticals Ltd.
16.22. Merck & Co., Inc.
16.23. Molbio Diagnostics Private Limited
16.24. Novartis AG
16.25. Otsuka Pharmaceutical Co., Ltd.
16.26. Pfizer Inc.
16.27. QIAGEN N.V.
16.28. Roche Diagnostics International AG
16.29. Sandoz International GmbH
16.30. Sanofi S.A.
16.31. Serum Institute of India Pvt. Ltd.
16.32. Thermo Fisher Scientific Inc.
16.33. Titan Biotech Limited
16.34. Viatris Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Mycobacterium Tuberculosis Market, Years Considered for the Study
FIGURE 2. Global Mycobacterium Tuberculosis Market, Research Design
FIGURE 3. Global Mycobacterium Tuberculosis Market, Research Framework
FIGURE 4. Global Mycobacterium Tuberculosis Market, Data Triangulation
FIGURE 5. Global Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Mycobacterium Tuberculosis Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Mycobacterium Tuberculosis Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Mycobacterium Tuberculosis Market Size, by Test Type, 2025 vs 2032 (%)
FIGURE 9. Global Mycobacterium Tuberculosis Market Size, by Test Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2025 vs 2032 (%)
FIGURE 11. Global Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Mycobacterium Tuberculosis Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Mycobacterium Tuberculosis Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Mycobacterium Tuberculosis Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Mycobacterium Tuberculosis Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Mycobacterium Tuberculosis Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Mycobacterium Tuberculosis Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Mycobacterium Tuberculosis Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Mycobacterium Tuberculosis Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Mycobacterium Tuberculosis Market Segmentation & Coverage
TABLE 2. Global Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 3. Global Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global First Line Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global First Line Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global First Line Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Second Line Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Second Line Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Second Line Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 11. Global Culture Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Culture Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Culture Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Interferon Gamma Release Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Interferon Gamma Release Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Interferon Gamma Release Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Microscopy Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Microscopy Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Microscopy Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Molecular Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Molecular Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Molecular Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Lamp Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Lamp Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Lamp Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Pcr Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Pcr Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Pcr Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Xpert Mtb Rif Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Xpert Mtb Rif Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Xpert Mtb Rif Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Skin Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Skin Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Skin Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 36. Global Drug Resistant Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Drug Resistant Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Drug Resistant Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Extensively Drug Resistant Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Extensively Drug Resistant Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Extensively Drug Resistant Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Multidrug Resistant Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Multidrug Resistant Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Multidrug Resistant Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Drug Susceptible Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Drug Susceptible Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Drug Susceptible Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 49. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Mycobacterium Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Mycobacterium Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. North America Mycobacterium Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. North America Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 82. North America Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 83. North America Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 84. North America Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 85. North America Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 86. North America Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. North America Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Latin America Mycobacterium Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Latin America Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 90. Latin America Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 91. Latin America Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 92. Latin America Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 93. Latin America Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 94. Latin America Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Latin America Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Europe Mycobacterium Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Europe Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 98. Europe Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 99. Europe Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 100. Europe Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 101. Europe Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 102. Europe Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Europe Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Middle East Mycobacterium Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Middle East Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 106. Middle East Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 107. Middle East Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 108. Middle East Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 109. Middle East Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 110. Middle East Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Middle East Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. Africa Mycobacterium Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Africa Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 114. Africa Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 115. Africa Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 116. Africa Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 117. Africa Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 118. Africa Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Africa Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. Global Mycobacterium Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. ASEAN Mycobacterium Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. ASEAN Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 123. ASEAN Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 124. ASEAN Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 125. ASEAN Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 126. ASEAN Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 127. ASEAN Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. ASEAN Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. GCC Mycobacterium Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. GCC Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 131. GCC Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 132. GCC Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 133. GCC Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 134. GCC Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 135. GCC Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. GCC Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. European Union Mycobacterium Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. European Union Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 139. European Union Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 140. European Union Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 141. European Union Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 142. European Union Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 143. European Union Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. European Union Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. BRICS Mycobacterium Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. BRICS Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 147. BRICS Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 148. BRICS Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 149. BRICS Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 150. BRICS Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 151. BRICS Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. BRICS Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. G7 Mycobacterium Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. G7 Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 155. G7 Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 156. G7 Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 157. G7 Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 158. G7 Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 159. G7 Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. G7 Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. NATO Mycobacterium Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. NATO Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 163. NATO Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 164. NATO Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 165. NATO Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 166. NATO Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 167. NATO Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. NATO Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Global Mycobacterium Tuberculosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. United States Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 171. United States Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 172. United States Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 173. United States Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 174. United States Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 175. United States Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 176. United States Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. United States Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Canada Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 179. Canada Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 180. Canada Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 181. Canada Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 182. Canada Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 183. Canada Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 184. Canada Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Canada Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. Mexico Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 187. Mexico Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 188. Mexico Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 189. Mexico Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 190. Mexico Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 191. Mexico Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 192. Mexico Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Mexico Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Brazil Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 195. Brazil Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 196. Brazil Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 197. Brazil Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 198. Brazil Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 199. Brazil Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 200. Brazil Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Brazil Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. United Kingdom Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 203. United Kingdom Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 204. United Kingdom Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 205. United Kingdom Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 206. United Kingdom Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 207. United Kingdom Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 208. United Kingdom Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. United Kingdom Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. Germany Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 211. Germany Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 212. Germany Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 213. Germany Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 214. Germany Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 215. Germany Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 216. Germany Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Germany Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. France Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 219. France Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 220. France Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 221. France Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 222. France Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 223. France Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 224. France Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. France Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Russia Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 227. Russia Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 228. Russia Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 229. Russia Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 230. Russia Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 231. Russia Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 232. Russia Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Russia Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Italy Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 235. Italy Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 236. Italy Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 237. Italy Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 238. Italy Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 239. Italy Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 240. Italy Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. Italy Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. Spain Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 243. Spain Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 244. Spain Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 245. Spain Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 246. Spain Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 247. Spain Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 248. Spain Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. Spain Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. China Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 251. China Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 252. China Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 253. China Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 254. China Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 255. China Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 256. China Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. China Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. India Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 259. India Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 260. India Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 261. India Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 262. India Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 263. India Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 264. India Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. India Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Japan Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 267. Japan Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 268. Japan Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 269. Japan Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 270. Japan Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 271. Japan Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 272. Japan Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 273. Japan Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. Australia Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 275. Australia Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 276. Australia Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 277. Australia Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 278. Australia Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 279. Australia Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 280. Australia Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. Australia Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. South Korea Mycobacterium Tuberculosis Market Size, 2017-2032 (USD Million)
TABLE 283. South Korea Mycobacterium Tuberculosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 284. South Korea Mycobacterium Tuberculosis Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 285. South Korea Mycobacterium Tuberculosis Market Size, by Molecular Tests, 2017-2032 (USD Million)
TABLE 286. South Korea Mycobacterium Tuberculosis Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 287. South Korea Mycobacterium Tuberculosis Market Size, by Drug Resistant Treatment, 2017-2032 (USD Million)
TABLE 288. South Korea Mycobacterium Tuberculosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. South Korea Mycobacterium Tuberculosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 290. Global Mycobacterium Tuberculosis Market Share, by Key Player, 2025
TABLE 291. Global Mycobacterium Tuberculosis Market, Key Experts

Companies Mentioned

  • Abbott Molecular Inc.
  • Actiza Pharmaceutical Private Limited
  • Anuh Pharma Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Cadila Healthcare Ltd.
  • CapitalBio
  • Care Formulation Labs Private Limited
  • Cepheid, Inc.
  • Cipla Ltd.
  • DaAN Gene Company
  • Eiken Chemical Co., Ltd.
  • GlaxoSmithKline plc
  • Hain Lifescience GmbH
  • Hetero Labs Ltd.
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Molbio Diagnostics Private Limited
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • QIAGEN N.V.
  • Roche Diagnostics International AG
  • Sandoz International GmbH
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Titan Biotech Limited
  • Viatris Inc.

Related Topics

Related Reports

Mycobacterium Tuberculosis Test Kit Market - Global Forecast 2026-2032 - Product Image

Mycobacterium Tuberculosis Test Kit Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market - Global Forecast 2026-2032 - Product Image

Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Mycobacterium Tuberculosis Market Report 2026 - Product Image

Mycobacterium Tuberculosis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 - Product Image

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036

  • Report
  • Global
From
Point of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Global Market Report 2026 - Product Image

Point of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Global Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.